News

JPM's strong NII outlook, NVS's blockbuster pipeline, and T's wireless momentum anchor today's top analyst picks.
Novartis has reported topline outcomes from the Phase III PSMAddition trial’s pre-specified interim analysis, where Pluvicto (lutetium (177 Lu) vipivotide tetraxetan), plus standard of care (SoC ...
Novartis announced topline results from a pre-specified interim analysis of the phase III PSMAddition trial. The trial met its primary endpoint with a statistically significant and clinically ...
Pluvicto is the only PSMA-targeted agent approved for PSMA-positive mCRPC and is the first targeted RLT to demonstrate a clinical benefit for patients with PSMA-positive mHSPC1. Novartis is ...
Marketing Novartis marketing breach sparks PMCPA call for companies to be ‘on high alert’ By Nick Paul Taylor Jun 4, 2025 9:30am PMCPA Novartis Pluvicto ...
FRANKFURT (Reuters) -Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate cancer, raising the prospect of treatment in an ...
On Monday, Novartis (NYSE:NVS) announced positive topline results from the Phase III PSMAddition trial, which showed that its targeted radioligand therapy/RLT, Pluvicto (lutetium (177Lu ...
Lantheus Holdings offers a compelling bull case, with PYLARIFY and DEFINITY driving valuation and strong growth prospects.
Novartis AG (NYSE:NVS) is one of the 10 Undervalued European Stocks to Invest in Now. Deutsche Bank analyst Emmanuel ...
Among those, Novartis' (NOVN.SW) Pluvicto prostate cancer treatment generated approximately $1.4 billion in revenue last year. Another radiopharmaceutical, Lutathera, for the treatment of GEP-NET ...
The Trump administration is weighing measures that would make it more expensive for pharmaceutical companies to conduct ...
Novartis AG (NYSE:NVS) is one of the 10 Undervalued European Stocks to Invest in Now. Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Novartis AG (NYSE:NVS) on June 9, setting ...